Dopamine: The Forgotten Felon in Type 2 Diabetes

Author(s): Sanjay Kalra, Bharti Kalra, Navneet Agrawal, Satish Kumar

Journal Name: Recent Patents on Endocrine, Metabolic & Immune Drug Discovery
Continued as New Advances on Endocrine Metabolic and Immune Diseases

Volume 5 , Issue 1 , 2011


This paper reviews recent patents and development related to bromocriptine and other dopaminergic agents, being used or suggested for use in the management of diabetes. The article discusses the contribution of dopaminergic pathways to glucose, energy and weight homeostasis. The mechanism of action of bromocriptine, its pharmacological properties, efficacy, safety and tolerability are assessed. The article also covers recent patents which may be utilized to improve the efficiency and tolerability of dopamine-based therapy in diabetes mellitus.

Keywords: Type 2 diabetes, obesity, bromocriptine, dopamine, dopaminergic agents, epidemic, insulin, Ominous Octet, gastrointestinal tract, kidney, brain, neurohormones, neurotransmitters, substantia nigra, ventral tegmental area, hypo-thalamus, mesolimbic path-ways, tonic, sexual gratification, Syrian hamsters, swine, drugs, pleiotropic, antipsychotics act, ergot alkaloids, Parkinson's disease, prolactinoma, acromegaly, gynaecological indications, peripartum cardiomyopathy, serum triglycerides, cyclosporine, plasma glucose, hypocaloric diet, placebo, syncopal migraine, lactation, giddiness

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2011
Published on: 01 March, 2012
Page: [61 - 65]
Pages: 5
DOI: 10.2174/187221411794351842

Article Metrics

PDF: 47